20% Special Sale Ends Today! Hurry Up!!!

New 3-Drug Regimen for Leprosy in India

New 3-Drug Regimen for Leprosy in India mind map
Recent News
January 2024
When
Starting April 1, 2025
Why
Eradicate leprosy
Ahead of UN Sustainable Development Goals
What
Shift from 2-drug to 3-drug regimen
For Pauci-Bacillary cases
Includes dapsone, rifampicin, clofazimine
Known as Multi-Drug Therapy
WHO endorsed
Where
Across India
Who
Indian Ministry of Health and Family Welfare
World Health Organization
National Leprosy Eradication Programme
Indian states and Union Territories
How
Advanced requisitions
Yearly submission for drugs
Unified implementation date
Significance
Accelerate leprosy eradication by 2027
Stops transmission at sub-national level
Simplifies administration and manufacturing
Challenges
Debate over necessity
Side effects like skin discoloration
Adequacy of 2-drug regimen
Way Forward
Monitor implementation
Address side effects
Ensure drug availability

In January 2024, the Indian Ministry of Health and Family Welfare announced the approval of a new 3-drug regimen for the treatment of Pauci-Bacillary (PB) leprosy, set to start on April 1, 2025. This initiative replaces the existing 2-drug regimen and includes dapsone, rifampicin, and clofazimine. Endorsed by the World Health Organization (WHO), it is part of India’s commitment to eradicate leprosy by 2027, aligning with the United Nations’ Sustainable Development Goals. While this transition is expected to accelerate the eradication of leprosy and simplify treatment processes, there are concerns about its necessity and potential side effects, such as skin discoloration.

Related Posts

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
X
Home Courses Plans Account
20% Special Sale Ends Today! Hurry Up!!!